C4 THERAPEUTICS INC's ticker is CCCC and the CUSIP is 12529R107. A total of 85 filers reported holding C4 THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,007,157 | -32.4% | 2,692,020 | 0.0% | 0.46% | -43.9% |
| Q2 2023 | $7,403,055 | -1.2% | 2,692,020 | +12.8% | 0.82% | +6.1% |
| Q1 2023 | $7,495,243 | -48.0% | 2,387,020 | -2.2% | 0.78% | -62.4% |
| Q4 2022 | $14,400,974 | +13.9% | 2,440,843 | +69.3% | 2.07% | +20.3% |
| Q3 2022 | $12,642,000 | +493.2% | 1,441,513 | +410.0% | 1.72% | +417.5% |
| Q2 2022 | $2,131,000 | -47.3% | 282,640 | +69.5% | 0.33% | -36.4% |
| Q1 2022 | $4,045,000 | -77.6% | 166,736 | -70.3% | 0.52% | -71.1% |
| Q4 2021 | $18,068,000 | -46.1% | 561,122 | -25.2% | 1.81% | -65.4% |
| Q3 2021 | $33,538,000 | +1.8% | 750,633 | -13.8% | 5.23% | +3.1% |
| Q2 2021 | $32,949,000 | +91.9% | 870,758 | +87.6% | 5.07% | +63.8% |
| Q1 2021 | $17,166,000 | +92.9% | 464,068 | +72.8% | 3.09% | +163.5% |
| Q4 2020 | $8,897,000 | – | 268,548 | – | 1.17% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| COMMODORE CAPITAL LP | 481,094 | $15,939,000 | 8.67% |
| Bain Capital Life Sciences Investors, LLC | 1,642,209 | $54,406,000 | 3.42% |
| Darwin Global Management, Ltd. | 228,595 | $7,573,000 | 2.11% |
| Asymmetry Capital Management, L.P. | 139,343 | $4,616,000 | 2.10% |
| Cormorant Asset Management, LP | 2,490,065 | $80,021,000 | 1.90% |
| Logos Global Management LP | 477,928 | $15,834,000 | 1.36% |
| SPHERA FUNDS MANAGEMENT LTD. | 443,824 | $14,601,000 | 1.30% |
| Soleus Capital Management, L.P. | 268,548 | $8,897,000 | 1.17% |
| P.A.W. CAPITAL CORP | 40,000 | $1,325,000 | 1.17% |
| RTW INVESTMENTS, LP | 2,149,228 | $68,679,000 | 1.15% |